Decaffeinated coffee consumption and risk of total and site-specific cancer.

IF 56.7 1区 医学 Q1 ONCOLOGY
Y Zhang, C Ma, L Zhao, L A Mucci, E L Giovannucci
{"title":"Decaffeinated coffee consumption and risk of total and site-specific cancer.","authors":"Y Zhang, C Ma, L Zhao, L A Mucci, E L Giovannucci","doi":"10.1016/j.annonc.2025.03.018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coffee is generally considered safe regarding cancer risk. However, concerns have emerged over methylene chloride, a chemical used in decaffeination, due to its carcinogenic properties. The potential cancer risk from methylene chloride residue in decaffeinated coffee remains unclear.</p><p><strong>Patients and methods: </strong>This prospective cohort study included 75,988 women (Nurses' Health Study, 1984-2020) and 45,349 men (Health Professionals Follow-up Study, 1986-2020). Decaffeinated coffee consumption was assessed at baseline and every four years using a validated food frequency questionnaire. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of total and 14 site-specific cancers associated with decaffeinated coffee consumption, adjusted for regular coffee intake and other potential confounding variables.</p><p><strong>Results: </strong>During up to 36 years of follow-up, we documented 34,120 incident cancer cases (22,688 in women and 11,432 in men). Overall, decaffeinated coffee intake was not associated with higher total cancer risk (per 1 cup/day higher intake, HR [95% CI], 1.00 [0.98-1.01]). For specific cancer type, an inverse association was observed for colorectal (0.96 [0.92-0.99]) and aggressive prostate cancer (0.93 [0.87-0.99]). An observed higher lung cancer risk for decaffeinated coffee attenuated to null when restricted to never-smokers. However, we observed elevated bladder cancer risk among male never-smokers: compared to non-drinkers, 0.1-0.9, 1-1.9, 2-2.9 and ≥3 cup/day of decaffeinated coffee intake were associated with HRs of 1.30 (95% CI, 1.01-1.68), 1.42 (1.00-2.03), 1.43 (0.91-2.23), and 1.79 (0.92-3.50), respectively, with borderline significant linear trends (P<sub>trend</sub> =0.06). This positive association remained robust in various sensitivity analyses and became even stronger with an 8-year lag. No association between decaffeinated coffee and bladder cancer was observed among women (P<sub>sex-heterogeneity</sub>=0.03).</p><p><strong>Conclusions: </strong>Higher decaffeinated coffee intake was not associated with total cancer risk. However, the observed significant higher risk of bladder cancer in men warrants further studies.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.annonc.2025.03.018","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Coffee is generally considered safe regarding cancer risk. However, concerns have emerged over methylene chloride, a chemical used in decaffeination, due to its carcinogenic properties. The potential cancer risk from methylene chloride residue in decaffeinated coffee remains unclear.

Patients and methods: This prospective cohort study included 75,988 women (Nurses' Health Study, 1984-2020) and 45,349 men (Health Professionals Follow-up Study, 1986-2020). Decaffeinated coffee consumption was assessed at baseline and every four years using a validated food frequency questionnaire. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of total and 14 site-specific cancers associated with decaffeinated coffee consumption, adjusted for regular coffee intake and other potential confounding variables.

Results: During up to 36 years of follow-up, we documented 34,120 incident cancer cases (22,688 in women and 11,432 in men). Overall, decaffeinated coffee intake was not associated with higher total cancer risk (per 1 cup/day higher intake, HR [95% CI], 1.00 [0.98-1.01]). For specific cancer type, an inverse association was observed for colorectal (0.96 [0.92-0.99]) and aggressive prostate cancer (0.93 [0.87-0.99]). An observed higher lung cancer risk for decaffeinated coffee attenuated to null when restricted to never-smokers. However, we observed elevated bladder cancer risk among male never-smokers: compared to non-drinkers, 0.1-0.9, 1-1.9, 2-2.9 and ≥3 cup/day of decaffeinated coffee intake were associated with HRs of 1.30 (95% CI, 1.01-1.68), 1.42 (1.00-2.03), 1.43 (0.91-2.23), and 1.79 (0.92-3.50), respectively, with borderline significant linear trends (Ptrend =0.06). This positive association remained robust in various sensitivity analyses and became even stronger with an 8-year lag. No association between decaffeinated coffee and bladder cancer was observed among women (Psex-heterogeneity=0.03).

Conclusions: Higher decaffeinated coffee intake was not associated with total cancer risk. However, the observed significant higher risk of bladder cancer in men warrants further studies.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Oncology
Annals of Oncology 医学-肿瘤学
CiteScore
63.90
自引率
1.00%
发文量
3712
审稿时长
2-3 weeks
期刊介绍: Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine. The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings. Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信